New P3 trial • Metastases
|
BRAF (B-raf proto-oncogene) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD163 (CD163 Molecule)
|
BRAF mutation • BRAF V600 • HLA-A*02
|
Opdualag (nivolumab/relatlimab-rmbw) • brenetafusp (IMC-F106C) • relatlimab (BMS-986016)